Lipopolysaccharide as a target for brucellosis vaccine design

Microbial Pathogenesis

Volumn 58, Issue , 2013, Pages 29-34

  Conde álvarez, Raquel ^a   Arce Gorvel, Vilma ^b   Gil Ramírez, Yolanda ^a   Iriarte, Maite ^a   Grilló, María Jesús ^c   Gorvel, Jean Pierre ^b   Moriyón, Ignacio ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^c PUBLIC UNIVERSITY OF NAVARRE   (Spain)

Author keywords

Attenuation; Brucellosis; Immunity; Lipopolysaccharide; Vaccine

Indexed keywords

BACTERIAL VACCINE; BACTERIUM LIPOPOLYSACCHARIDE; BRUCELLA ABORTUS DELTA WADC VACCINE; BRUCELLA VACCINE; ENDOTOXIN; INTERLEUKIN 12; LIPID A; OLIGOSACCHARIDE; OUTER MEMBRANE PROTEIN; POLYMYXIN B; PROTEIN MD 2; S 19; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID;

ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BRUCELLOSIS; COLONY FORMING UNIT; COMPLEMENT ACTIVATION; CYTOKINE RESPONSE; DENDRITE; DRUG DESIGN; GENE MUTATION; HUMAN; INFECTION PREVENTION; INNATE IMMUNITY; MOLECULAR RECOGNITION; MUTANT; NONHUMAN; OPEN READING FRAME; PARASITE VIRULENCE; PRIORITY JOURNAL; PROTEIN BINDING; TH1 CELL; TYPE IV SECRETION SYSTEM; UPREGULATION; VACCINE PRODUCTION; WADC GENE;

ANIMALS; BACTERIAL LOAD; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; GENE KNOCKOUT TECHNIQUES; GLYCOSYLTRANSFERASES; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; O ANTIGENS; SPLEEN; VACCINES, ATTENUATED;

ANIMALIA; BOS; BRUCELLA; BRUCELLA MELITENSIS BIOVAR ABORTUS; MUS; NEGIBACTERIA;

EID: 84875864100     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2012.11.011     Document Type: Article

References (35)

1. Moreno E., Cloeckaert A., Moriyón I. Brucella evolution and taxonomy. Vet Microbiol 2002, 90:209-227.
2. Chain P.S., Comerci D.J., Tolmasky M.E., Larimer F.W., Malfatti S.A., Vergez L.M., et al. Whole-genome analyses of speciation events in pathogenic brucellae. Infect Immun 2005, 73:8353-8361.
3. Dean A.S., Crump L., Greter H., Schelling E., Zinsstag J. Global burden of human brucellosis: a systematic review of disease frequency. PLoS Negl Trop Dis 2012, 6:e1865.
4. Seimenis A., Morelli D., Mantovani A. Zoonoses in the Mediterranean region. Ann Ist Super Sanita 2006, 42:437-445.
5. Maudlin I., Weber S. The control of neglected zoonotic diseases: a route to poverty alleviation. WHO/SDE/FOS/2006.1 2006, Geneva.
6. Seimenis A. Zoonoses and poverty - a long road to the alleviation of suffering. Vet Ital 2012, 48:5-13.
7. Nicoletti P. Vaccination. Animal brucellosis 1990, 283-299. CRC Press, Boca Raton. K.H. Nielsen, J.R. Duncan (Eds.).
8. Garin-Bastuji B., Blasco J.M., Grayon M., Verger J.M. Brucella melitensis infection in sheep: present and future. Vet Res 1998, 29:255-274.
9. Blasco J.M., Molina-Flores B. Control and eradication of Brucella melitensis infection in sheep and goats. Vet Clin North Am Food Anim Pract 2011, 27:95-104.
10. Hoover D.L., Nikolich M.P., Izadjoo M.J., Borschel R.H., Bhattacharjee A.K. Develpment of new Brucella vaccines by molecular methods. Brucella: molecular and cellular biology 2004, 369-402. Horizon Scientific Press Ltd, Norfolk, U.K. I. López-Goñi, I. Moriyón (Eds.).
11. Ariza J., Bosilkovski M., Cascio A., Colmenero J.D., Corbel M.J., Falagas M.E., et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS.Med 2007, 4:e317.
12. Jacques I., Verger J.M., Laroucau K., Grayon M., Vizcaíno N., Peix A., et al. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep. Vaccine 2007, 25:794-805.
13. Fiorentino M.A., Campos E., Cravero S., Arese A., Paolicchi F., Campero C., et al. Protection levels in vaccinated heifers with experimental vaccines Brucella abortus M1-luc and INTA 2. Vet Microbiol 2008, 132:302-311.
14. Kahl-McDonagh M.M., Elzer P.H., Hagius S.D., Walker J.V., Perry Q.L., Seabury C.M., et al. Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis. Vaccine 2006, 24:5169-5177.
15. Phillips R.W., Elzer P.H., Robertson G.T., Hagius S.D., Walker J.V., Fatemi M.B., et al. A Brucella melitensis high-temperature-requirement A (htrA) deletion mutant is attenuated in goats and protects against abortion. Res Vet Sci 1997, 63:165-167.
16. Gee J.M., Kovach M.E., Grippe V.K., Hagius S., Walker J.V., Elzer P.H., et al. Role of catalase in the virulence of Brucella melitensis in pregnant goats. Vet Microbiol 2004, 102:111-115.
17. Cheville N.F., Olsen S.C., Jensen A.E., Stevens M.G., Florance A.M., Houng H.S., et al. Bacterial persistence and immunity in goats vaccinated with a purE deletion mutant or the parental 16M strain of Brucella melitensis. Infect Immun 1996, 64:2431-2439.
18. Monreal D., Grilló M.J., González D., Marín C.M., de Miguel M.J., López-Goñi I., et al. Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model. Infect Immun 2003, 71:3261-3271.
19. Moriyón I., Grilló M.J., Monreal D., González D., Marín C.M., López-Goñi I., et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res 2004, 35:1-38.
20. González D., Grilló M.J., de Miguel M.J., Ali T., Arce-Gorvel V., Delrue R.M., et al. Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS One 2008, 3:e2760.
21. Barrio M.B., Grilló M.J., Muñoz P.M., Jacques I., González D., de Miguel M.J., et al. Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep. Vaccine 2009, 27:1741-1749.
22. Barquero-Calvo E., Chaves-Olarte E., Weiss D.S., Guzmán-Verri C., Chacón-Díaz C., Rucavado A., et al. Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection. PLoS One 2007, 2:e631.
23. Lapaque N., Moriyón I., Moreno E., Gorvel J.P. Brucella lipopolysaccharide acts as a virulence factor. Curr.Opin. Microbiol 2005, 8:60-66.
24. Moriyón I. Against gram-negative bacteria: the LPS case. Intracellular pathogens in membrane interactions and vacuole biogenesis 2003, 204-230. Landes Bioscience/Eurekah.com, Georgetown, Texas. J.P. Gorvel (Ed.).
25. Palacios-Chaves L., Conde-álvarez R., Gil-Ramírez Y., Zuñiga-Ripa A., Barquero-Calvo E., Chacón-Díaz C., et al. Brucella abortus ornithine lipids are dispensable outer membrane components devoid of a marked pathogen-associated molecular pattern. PLoS One 2011, 6:e16030.
26. Park B.S., Song D.H., Kim H.M., Choi B.S., Lee H., Lee J.O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458:1191-1195.
27. Kastowsky M., Gutberlet T., Bradaczek H. Molecular modelling of the three-dimensional structure and conformational flexibility of bacterial lipopolysaccharide. J Bacteriol 1992, 174:4798-4806.
28. Gruber A., Mancek M., Wagner H., Kirschning C.J., Jerala R. Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition. J Biol Chem 2004, 279:28475-28482.
29. Iriarte M., González D., Delrue R.M., Monreal D., Conde-álvarez R., López-Goñi I., et al. Brucella LPS: structure, biosynthesis and genetics. Brucella: molecular and cellular biology 2004, 159-192. Horizon Scientific Press Ltd, Norfolk, U.K. I. López-Goñi, I. Moriyón (Eds.).
30. Lapaque N., Takeuchi O., Corrales F., Akira S., Moriyón I., Howard J.C., et al. Differential inductions of TNF-alpha and IGTP, IIGP by structurally diverse classic and non-classic lipopolysaccharides. Cell Microbiol 2006, 8:401-413.
31. Velasco J., Bengoechea J.A., Brandenburg K., Lindner B., Seydel U., González D., et al. Brucella abortus and its closest phylogenetic relative, Ochrobactrum spp., differ in outer membrane permeability and cationic peptide resistance. Infect Immun 2000, 68:3210-3218.
32. Conde-Alvarez R., Arce-Gorvel V., Iriarte M., Manček-Keber M., Barquero-Calvo E., Palacios-Chaves L., et al. The lipopolysaccharide core of Brucella abortus acts as a shield against innate immunity recognition. PLoS Pathog 2012, 8:e1002675EP.
33. Crasta O.R., Folkerts O., Fei Z., Mane S.P., Evans C., Martino-Catt S., et al. Genome sequence of Brucella abortus vaccine strain S19 compared to virulent strains yields candidate virulence genes. PLoS One 2008, 3:e2193.
34. Chacón-Díaz C., Muñoz-Rodríguez M., Barquero-Calvo E., Guzmán-Verri C., Chaves-Olarte E., Grilló M.J., et al. The use of green fluorescent protein as a marker for Brucella vaccines. Vaccine 2011, 29:577-582.
35. Zinsstag J., Schelling E., Roth F., Bonfoh B., de S.D., Tanner M. Human benefits of animal interventions for zoonosis control. Emerg Infect Dis 2007, 13:527-531.